Olaf van Tellingen
Impact in
- Oncology top 0.1%
- Drug Transport and Resistance Mechanisms
- Cancer Treatment and Pharmacology
- Pharmacology top 0.05%
- Pharmacogenetics and Drug Metabolism
Papers in
- Oncology 167
- Drug Transport and Resistance Mechanisms 109
- Cancer Treatment and Pharmacology 45
-
- Cancer therapeutics and mechanisms 37
- Co-authors
- Jos H. Beijnen (140 shared papers)Alfred H. Schinkel (32 shared papers)Piet Borst (11 shared papers)Jan H.M. Schellens (42 shared papers)Els Wagenaar (18 shared papers)Alex Sparreboom (8 shared papers)Martin A. van der Valk (4 shared papers)Mark C. de Gooijer (31 shared papers)
- Journals
- Cancer Chemotherapy and Pharmacology (15 papers)Investigational New Drugs (13 papers)Clinical Cancer Research (12 papers)Cancer Research (10 papers)British Journal of Cancer (10 papers)
- Partner nations
- NetherlandsUnited StatesUnited Kingdom
In The Last Decade
Olaf van Tellingen
232 papers receiving 15.6k citations
Olaf van Tellingen's Hit Papers
Peers
Comparison fields: 5 of 143
- Oncology 10.0k
- Pharmacology 1.8k
- Pediatrics, Perinatology and Child Health 3.8k
- Genetics 1.8k
- Pharmaceutical Science 672
Countries citing papers authored by Olaf van Tellingen
This map shows the geographic impact of Olaf van Tellingen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Olaf van Tellingen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Olaf van Tellingen more than expected).
Fields of papers citing papers by Olaf van Tellingen
This network shows the impact of papers produced by Olaf van Tellingen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Olaf van Tellingen. The network helps show where Olaf van Tellingen may publish in the future.
Co-authors
The 25 scholars most cited alongside Olaf van Tellingen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 238 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs Hit paper breakdown → | 1994 | 1812 |
| 2 | Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins Hit paper breakdown → | 1997 | 771 |
| 3 | Overcoming the blood–brain tumor barrier for effective glioblastoma treatment Hit paper breakdown → | 2015 | 764 |
| 4 | Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine Hit paper breakdown → | 1997 | 749 |
| 5 | Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Hit paper breakdown → | 2002 | 590 |
| 6 | 1995 | 428 | |
| 7 | 2013 | 312 | |
| 8 | 2005 | 283 | |
| 9 | 1999 | 264 | |
| 10 | Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. | 1996 | 261 |
| 11 | 2007 | 236 | |
| 12 | 2007 | 218 | |
| 13 | 2007 | 208 | |
| 14 | 2014 | 208 | |
| 15 | 2004 | 190 | |
| 16 | Increased penetration of paclitaxel into the brain by inhibition of P-Glycoprotein. | 2003 | 190 |
| 17 | 2007 | 189 | |
| 18 | 2016 | 188 | |
| 19 | 1998 | 178 | |
| 20 | 1997 | 173 |
About Olaf van Tellingen
Olaf van Tellingen is a scholar working on Oncology, Molecular Biology, Pediatrics, Perinatology and Child Health, Genetics and Pharmacology, having authored 238 papers that have together received 16.1k indexed citations. Recurring topics across this work include Drug Transport and Resistance Mechanisms (109 papers), Pharmacological Effects and Toxicity Studies (52 papers), Cancer Treatment and Pharmacology (45 papers), Glioma Diagnosis and Treatment (39 papers), Cancer therapeutics and mechanisms (37 papers), Pharmacogenetics and Drug Metabolism (36 papers), Nanoparticle-Based Drug Delivery (10 papers) and Radiopharmaceutical Chemistry and Applications (10 papers). The work is most often cited by research in Oncology (10.0k citations), Pharmacology (1.8k citations), Pediatrics, Perinatology and Child Health (3.8k citations), Genetics (1.8k citations) and Pharmaceutical Science (672 citations). Olaf van Tellingen has collaborated with scholars based in Netherlands, United States and United Kingdom. Frequent co-authors include Jos H. Beijnen, Alfred H. Schinkel, Piet Borst, Jan H.M. Schellens, Els Wagenaar, Alex Sparreboom, Martin A. van der Valk, Mark C. de Gooijer, Tessa Buckle and Liesbeth van Deemter. Their work appears in journals such as Cancer Chemotherapy and Pharmacology, Investigational New Drugs, Clinical Cancer Research, Cancer Research and British Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.